HealthUS FDA approves Replimune skin cancer drug after prior rejections
The U.S. Food and Drug Administration has approved Replimune’s drug for a difficult-to-treat form of skin cancer. The company said the decision came on Thursday. It gives the biotechnology firm its first product to reach the market. The approval follows multiple earlier regulatory setbacks for the drug.
R
Reuters★★★☆☆2026-08-06 22:45Original
US FDA approves Replimune skin cancer drug after prior rejections
Health